MDT

87.16

-1.11%↓

115.07

-0.13%↓

VEEV

150.54

-3.69%↓

HQY

79.25

-4.22%↓

TLRY

6.6

-2.22%↓

MDT

87.16

-1.11%↓

115.07

-0.13%↓

VEEV

150.54

-3.69%↓

HQY

79.25

-4.22%↓

TLRY

6.6

-2.22%↓

MDT

87.16

-1.11%↓

115.07

-0.13%↓

VEEV

150.54

-3.69%↓

HQY

79.25

-4.22%↓

TLRY

6.6

-2.22%↓

MDT

87.16

-1.11%↓

115.07

-0.13%↓

VEEV

150.54

-3.69%↓

HQY

79.25

-4.22%↓

TLRY

6.6

-2.22%↓

MDT

87.16

-1.11%↓

115.07

-0.13%↓

VEEV

150.54

-3.69%↓

HQY

79.25

-4.22%↓

TLRY

6.6

-2.22%↓

Home・Akciju saraksts・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Atvērts

12.68 -7.45

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

12.32

Max

13.52

Galvenie mērījumi
By Trading Economics
Ienākumi	-23M -14M
Pārdošana	-22M 72M
Peļņas marža	-18.944
Darbinieki	624
EBITDA	-23M -6.4M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+40.57% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 30. apr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-639M 2.2B
Iepriekšējā atvēršanas cena	20.13
Iepriekšējā slēgšanas cena	12.68

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bullish Evidence

8.81 / 10.18 Atbalsts un pretestība

Adaptive Biotechnologies Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB: Higher Energy Prices to Raise Production, Consumer Costs

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

2026. g. 9. apr. 23:44 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

2026. g. 9. apr. 23:34 UTC

Tirgus saruna

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

2026. g. 9. apr. 23:14 UTC

Tirgus saruna

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

2026. g. 9. apr. 23:14 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 9. apr. 23:07 UTC

Tirgus saruna

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

2026. g. 9. apr. 22:54 UTC

Tirgus saruna

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

2026. g. 9. apr. 22:31 UTC

Galvenie ziņu notikumi

Trump on Truth Social: 'That Is Not the Agreement We Have!'

2026. g. 9. apr. 22:31 UTC

Galvenie ziņu notikumi

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

2026. g. 9. apr. 20:57 UTC

Galvenie ziņu notikumi

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

2026. g. 9. apr. 20:55 UTC

Peļņas

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

2026. g. 9. apr. 20:55 UTC

Peļņas

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

2026. g. 9. apr. 20:55 UTC

Peļņas

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

2026. g. 9. apr. 20:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 9. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. apr. 20:40 UTC

Iegādes, apvienošanās, pārņemšana

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

2026. g. 9. apr. 20:39 UTC

Iegādes, apvienošanās, pārņemšana

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

2026. g. 9. apr. 20:39 UTC

Iegādes, apvienošanās, pārņemšana

Rowan Digital Infrastructure Announces Strategic Recapitalization

2026. g. 9. apr. 20:25 UTC

Iegādes, apvienošanās, pārņemšana

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

2026. g. 9. apr. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 9. apr. 19:30 UTC

Galvenie ziņu notikumi

How Digital Currencies Have Helped Iran -- WSJ

Salīdzinājums

Cenas izmaiņa

Adaptive Biotechnologies Corp Prognoze

Cenas mērķis

By TipRanks

40.57% augšup

Prognoze 12 mēnešiem

Vidējais 20.86 USD 40.57%

Augstākais 22 USD

Zemākais 20 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Adaptive Biotechnologies Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Adaptive Biotechnologies Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

8.81 / 10.18Atbalsts un pretestība

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.